

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
15 September 2005 (15.09.2005)

PCT

(10) International Publication Number
WO 2005/084198 A2

(51) International Patent Classification: **Not classified**

Paris (FR). BESSIS, Natacha [FR/FR]; 73, Bld Voltaire, F-75011 Paris (FR).

(21) International Application Number:

PCT/US2005/005890

(74) Agents: **BROWDY AND NEIMARK, P.L.L.C.** et al.; 624 Ninth Street N.W., Suite 300, Washington, District of Columbia 20001-5303 (US).

(22) International Filing Date: 25 February 2005 (25.02.2005)

English

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/547,848 27 February 2004 (27.02.2004) US


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (for all designated States except US): **VAX-CONSULTING** [FR/FR]; c/o ZAGURY, 117, rue Vieille du Temple, F-75003 Paris (FR).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,

[Continued on next page]

(54) Title: PEPTIDES OF IL1 BETA AND TNF ALPHA AND METHOD OF TREATMENT USING SAME



(57) Abstract: The present invention relates to peptides derived from the proinflammatory cytokines, interleukin-1 β , (IL1 β) and tumor necrosis factor α , (TNF α), and their use in human or veterinary therapy, such as to generally treat diseases linked to the overproduction of IL1 β or TNF α as well as acute or chronic inflammatory diseases, rheumatoid arthritis, septic shock, autoimmune diabetes, graft rejection in the host, etc.

WO 2005/084198 A2



SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- *without international search report and to be republished upon receipt of that report*